|View printer-friendly version|
|July 29, 2013 8:01 a.m.|
|The Potential for New Therapeutic Approaches: Global Research Collaboration Examines Multiple Pathways of Neuroprotection in Huntington Disease|
JERUSALEM--(BUSINESS WIRE)--Jul. 29, 2013--
The collaboration brings together the field's leading scientific researchers from
Huntington disease stems from genetically-programmed degeneration of brain cells in selected areas of the brain. This degeneration results in uncontrolled movements, loss of intellectual faculties, and personality and emotional disturbances. Current therapy for HD consists of symptom management. There are no treatment options that control, stop or reverse the progression of the disease.
This innovative research approach aims to examine the potential to protect neurons against the neuronal degeneration characteristic of HD through multiple pathways such as; immune dysfunction in the periphery, inflammation in astrocytes and microglia, astrocyte activation in the brain and other important pathways.
"HD is a neurodegenerative condition that places an immense burden on the individual, their family and the community," said Dr.
The collaboration consists of leading Huntington disease research centers and others, purposely selected for their expertise in specific pathways relevant to HD. They include:
"This is a wonderful opportunity to make significant inroads into exciting new possible treatments," said Prof.
About Huntington disease
Huntington disease is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and psychiatric problems. It typically becomes noticeable in mid-adult life. HD is the most common genetic cause of abnormal involuntary writhing movements called chorea, which is why the disease used to be called Huntington chorea.
HD is a familial disease, passed from parent to child through a gene mutation. Each child of an HD parent has a 50-50 chance of inheriting the HD gene. If a child does not inherit the HD gene, he or she will not develop the disease and cannot pass it to subsequent generations. A person who inherits the HD gene will sooner or later develop the disease. The worldwide prevalence of HD is at least 1 in every 10,000 people.
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition for our innovative products, especially Copaxone® (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our innovative R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S. and
Teva Pharmaceutical Industries Ltd.